Ñî¹óåú´«Ã½Ò•îl

Primary care physicians’ compensation saw a bigger boost in 2022 than a year earlier but the gain wasn't enough to offset last year's inflationary pressures. Median total compensation for primary care doctors rose 4.41% last year, compared with 2.13% in 2021, according to a Medical Group Management Association analysis released Thursday of data from more than 190,000 physicians. (Kacik, 5/26)

Stimwave’s pitch was alluring. As a startup tackling chronic pain with nerve-stimulating devices, it promised to release patients from the stranglehold of addictive painkillers. And unlike its competitors, whose devices required patients to have clunky batteries implanted in their bodies, Stimwave’s system came with a sleek, wearable battery attached to thin wires under the skin. But under financial pressure, the company’s promise soon crumbled into fraud. (Lawrence, 5/30)

A deal for an out-of-state nonprofit to acquire two Rhode Island-based hospitals and their subsidiaries reached a new milestone on Friday, after the two organizations submitted their proposal to state regulators. (Gagosz, 5/26)

Walgreens Boots Alliance Inc (WBA.O) said on Friday it would slash its corporate staff by about 10%, as it streamlines operations and focuses on consumer-facing healthcare businesses. None of the 504 roles being cut are based at its stores, micro-fulfillment outlets or call centers, a company spokesperson told Reuters. (5/26)

The U.S. Food and Drug Administration (FDA) has approved Lexicon Pharmaceuticals Inc's (LXRX.O) drug for a broad treatment of heart failure, including in adult patients with type 2 diabetes, the company said on Friday. Shares of the company rose 13% in extended trading. The oral drug, sotagliflozin, is the company's first to be approved by the U.S. health agency and will be sold under the brand name Inpefa. It had previously failed to win U.S. approval as an add-on to insulin therapy for type 1 diabetes. (Mandowara, 5/26)

Biotech company Alnylam Pharmaceuticals Inc (ALNY.O) filed new lawsuits on Friday against Pfizer Inc (PFE.N) and Moderna Inc (MRNA.O) in Delaware federal court, again claiming that the companies' COVID-19 vaccines infringe its patents. The new lawsuits mark the third time Alnylam has sued Pfizer and Moderna in Delaware for allegedly violating its patent rights in lipid nanoparticle (LNP) technology, which the vaccines use to deliver genetic material into the body. (Brittain, 5/26)

The European Medicines Agency (EMA) said on Friday it had recommended revoking marketing authorisation for Novartis' (NOVN.S) sickle cell disease drug Adakveo. The recommendation follows a review by EMA's human medicines committee (CHMP) that concluded the benefits of the drug did not outweigh risks, according to the regulator. (5/26)

In early November 2022, the FBI alerted Delaware’s Board of Nursing to a scheme in which an owner of four Florida-based schools sold fake college degrees to students who then used the phony credentials to get nursing licenses from states nationwide. Pamela Zickafoose, executive director of Delaware’s board, said she wasted no time. On Nov. 15, 2022, her board annulled the licenses of 26 nurses who had bought degrees for about $17,000 each. Among the 26 was a registered nurse from Philadelphia who obtained a license to practice in Delaware — and in Pennsylvania, state records show. (Ruderman, 5/30)